Tenet Healthcare Corp (THC)
UndervaluedFundamental
69
Price
$268.45
Market Cap
$21.67B
Part 1 · What the company is worth
Overview
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; pediatric quaternary care services through heart, liver, and kidney transplants programs; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging technology, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services comprising orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. Further, the company operates acute care and specialty hospitals, off-campus emergency departments, imaging centers, urgent care centers, and micro-hospitals, as well as ambulatory surgery centers and surgical hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$21.81B
Trailing 12 months (through 6/30/2026)
Net Income
$3.17B
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$2.53B
Total Equity
$4.22B
Total Liabilities
$20.70B
Current Ratio
1.41
Interest Coverage
5.54
Debt/EBITDA
3.03
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$613.94
Current Price
$268.45
Margin of Safety
+56.3%
Fair Value Range
$399.06 - $828.81
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
10.35
ROE
56.1%
P/B Ratio
4.64
P/FCF
7.15
Gross Margin
-
ROIC
14.3%
Profitability Radar
Value Creation (Economic Moat)
ROIC
14.3%
WACC
8.8%
ROIC − WACC
+5.4 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- EPS CAGR 40.13%
- Price CAGR 33.74%
- ROIC 14.3%
- P/FCF 7.15
- Operating margin 20.8%
- Positive free cash flow
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- ROE 50.6%
- Earnings surprise, average 20.9%
- PEG ratio 0.30
- Earnings quality (operating cash flow / net income) 1.26
- Net margin trend 14.6% vs 11.6%
- Piotroski F-Score 5/9
Failed (8)
- P/B ratio 4.64
- Debt/equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue growth 5Y 3.9%
- Share dilution 23.0%
Unavailable (2)
- Gross margin –
- Dividend payout –
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Saumya Sutaria M.D. | Chairman & CEO | 52 |
| Mr. Sun K. Park | Executive VP & CFO | 49 |
| Ms. Lisa Y. Foo | Executive VP & Chief Operating Officer | 34 |
| Ms. Paola M. Arbour | Executive VP & Chief Information Officer | 61 |
| Mr. Thomas W. Arnst | EVP, Chief Administrative Officer, Chief Risk Officer, General Counsel & Corporate Secretary | 62 |
| Mr. John Michael Grooms | Senior VP, Controller & Principal Accounting Officer | 47 |
| Mr. William McDowell III | Vice President of Investor Relations | - |
| Ms. Jana Durfee | Senior VP & Chief Compliance Officer | - |
| Mr. Michael T. Maloney | Executive Vice President of Corporate Development | - |
| Mr. Clint Hailey | Chief Managed Care Officer & Senior VP | 60 |
Audit Risk
3
Board Risk
3
Compensation Risk
2
Shareholder Rights Risk
1
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-17
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-29
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-22
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much THC moves, measured on its daily prices.
More volatile than 66% of the tracked stocks (90-day volatility).
- Volatility 30d
- 24.2%
- Volatility 90d
- 43.9%
- Beta vs S&P 500 (1y)
- 0.49Correlation 0.14
- Max drawdown (12m)
- -34.1%
- ATR (14d, % of price)
- 2.68%
Earnings reactions
How THC moved around its past quarterly results.
Next earnings release
Oct 29, 2026 · In 5 days · Before the open
EPS estimate: 4.68Revenue estimate: $5.5B
What usually happens
- Over the last 12 releases the stock moved a median of 9.9% the next day, up or down.
- Next-day moves: up 8, down 4 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | After the close | 4.26 | 6.12 | +43.6% | +18.1% | +17.2% | +27.0% |
| Apr 30, 2026 | Before the open | 4.22 | 4.82 | +14.1% | +1.9% | -1.7% | +8.0% |
| Feb 11, 2026 | Before the open | 4.09 | 4.70 | +14.8% | -2.4% | +17.3% | +20.1% |
| Oct 28, 2025 | Before the open | 3.34 | 3.70 | +10.9% | -2.9% | -5.3% | -6.8% |
| Jul 22, 2025 | Before the open | n/a | n/a | n/a | +5.0% | -10.7% | -10.4% |
| Apr 29, 2025 | Before the open | n/a | n/a | n/a | +3.3% | +11.7% | +20.3% |
| Feb 12, 2025 | Before the open | n/a | n/a | n/a | -3.4% | -9.1% | -2.3% |
| Oct 29, 2024 | Before the open | n/a | n/a | n/a | +5.9% | +16.7% | +16.4% |
| Jul 24, 2024 | Before the open | n/a | n/a | n/a | +5.3% | +4.8% | +8.3% |
| Apr 30, 2024 | Before the open | n/a | n/a | n/a | +5.9% | +13.3% | +23.4% |
| Feb 8, 2024 | Before the open | n/a | n/a | n/a | +1.7% | +1.0% | -0.2% |
| Oct 30, 2023 | After the close | n/a | n/a | n/a | -1.3% | +0.8% | +2.6% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on THC and what the price did next.
- 2/20/2026PositiveThe Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts
- +1 day
- +2.7%
- +3 days
- +2.6%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for THC.
- 2/20/2026POSITIVEThe Analyst Verdict: Tenet Healthcare In The Eyes Of 12 Experts
Recent analyst ratings for Tenet Healthcare (THC) show a predominantly positive sentiment, with multiple experts maintaining or reinstating "Buy" ratings. This suggests a favorable outlook for the stock, based on fundamental analysis or future growth prospects.